Prosecution Insights
Last updated: November 04, 2026
Application No. 18/258,861

MEANS AND METHODS OF PREVENTING, TREATING AND DETECTING INFECTIONS

Final Rejection §112
Filed
Jun 22, 2023
Priority
Dec 22, 2020 — EU 20216717.7 +2 more
Examiner
FOLEY, SHANON A
Art Unit
1671
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Leopold GmbH
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
728 granted / 994 resolved
+13.2% vs TC avg
Strong +18% interview lift
Without
With
+18.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
41 currently pending
Career history
1031
Total Applications
across all art units

Statute-Specific Performance

§101
6.8%
-33.2% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
28.0%
-12.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 994 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The examiner of your application has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1671, Examiner Foley. Claim Objections Claim 124 recites the limitation "the virus" in the first four words of line 2. There is insufficient antecedent basis for this limitation prior to recitation. Replacing “the” with “a” is more precise since the virus recited is generic and encompasses any number therein and not “the” specific virus. Moreover, replacing “the” with “a” in the first four words of line 2 would be in agreement with recitation of “a virus” in the last few words of line 2. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 124-126, 128-133, and 135-143 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 124 has been amended to recite that virus neutralizing antibodies have increased binding affinity to the virus as a result of the instant method. A search for “affinity” in the instant published application, USPgPub 2024/0050366, revealed five recitations of “affinity”: Paragraph [0467] discusses chitosan binding to SARS-CoV-2 viruses; Paragraph [0525] discusses binding affinity of SARS-CoV-2 RBD to a human ACE2; Paragraph [0526] notes “MO Affinity Analysis software”; Paragraph [0527] states parameters for chitosan…binding to Snap tag RBD; and Paragraph [0529] discusses nanomolar binding affinity of chitosan… to mini RBD of SARS-Cov2. There is no discussion of binding affinity between a neutralizing antibody and a coronavirus or “increasing the binding affinity” of a virus neutralizing antibody for the virus, as recited. There is no mention of measuring or characterizing antibody-antigen by surface plasmon resonance technology, kinetics, or interactions. There is no indication that contacting a fluid containing a coronavirus and coronavirus neutralizing antibodies with chitosan or a salt thereof, galactose, mannose, caffeine, or any combination thereof, would result in increasing the binding affinity of virus neutralizing antibodies for the virus, as recited. No support for this concept can be found in the specification and applicant did not point to any support in the instant disclosure. Therefore, increasing virus neutralizing antibody binding affinity to a coronavirus in a fluid by contacting the fluid with chitosan or a salt thereof, galactose, mannose, caffeine, or any combination thereof, as recited, is new matter. Claims 124-126, 128-133, and 135-143 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Claim 124 has been amended to recite that virus neutralizing antibodies have increased binding affinity to the virus as a result of the instant method. A search for “affinity” in the instant published application, USPgPub 2024/0050366, revealed five recitations of “affinity”: Paragraph [0467] discusses chitosan binding to SARS-CoV-2 viruses; Paragraph [0525] discusses binding affinity of SARS-CoV-2 RBD to a human ACE2; Paragraph [0526] notes “MO Affinity Analysis software”; Paragraph [0527] states parameters for chitosan…binding to Snap tag RBD; and Paragraph [0529] discusses nanomolar binding affinity of chitosan… to mini RBD of SARS-Cov2. There is no discussion of binding affinity between a neutralizing antibody and a coronavirus or “increasing the binding affinity” of a virus neutralizing antibody for the virus, as recited. There is no mention of measuring or characterizing antibody-antigen by surface plasmon resonance technology, kinetics, or interactions. There is no indication that contacting a fluid containing a coronavirus and coronavirus neutralizing antibodies with chitosan or a salt thereof, galactose, mannose, caffeine, or any combination thereof, would result in increasing the binding affinity of virus neutralizing antibodies for the virus, as recited. No support for this concept can be found in the specification and applicant did not point to any support in the instant disclosure. Instant Figures 15A, 15B, 17A, and 17B depict neutralizing antibody titers to SARS-COV-02 RBD-protein and the SARS-COV-02 N-protein, respectively, in the presence or absence of chitosan, discussed in instant paragraphs [0035, 0037, 0339] and Example 3 bridging paragraphs [0532-0538] of the instant published application, USPgPub 2024/0050366. While the presence of chitosan results in an elevation (quantity) of antibody binding, depicted in the Figures, there is no test for antibody affinity to either SARS-CoV-2 target or any data presented that conveys increased binding affinity of the SARS-CoV-2 neutralizing antibodies to SARS-COV-02 RBD-protein and the SARS-COV-02 N-protein, respectively, in the presence or absence of chitosan. Paragraph [0532] identifies the commercial ELISA assay used to generate the data depicted in Figures 15 and 17 as the Proteintech® ELISA RBD Covid IgG ELISA kit. According to section, “product description” obtained online (and provided as an attachment to this correspondence), the ELISA kit is an indirect quantitative measurement of the human IgG for SARS-CoV-2 S-RBD in serum and plasma. Color intensity, measured at a 450 nm, is proportional to the quantity of bound protein. There is no mention of the assay providing information on antibody affinity to the SARS-CoV-2 S-RBD. Quantitation of antibody concentrations measured with the same ELISA assay are confirmed in “ELISA-based anti-SARS-CoV-2 antibody detection” and Figure 3 of Zhang et al. (Frontiers of medicine. 2022 Feb; 16 (1): 93-101). The skilled artisan would not predict success for measuring neutralizing antibody affinity or determining an increase in virus neutralizing antibody binding affinity to a coronavirus in a fluid with the Proteintech® ELISA RBD Covid IgG ELISA kit used in instant Example 3. Chi et al. (Nature communications. 2020 Sep 10; 11 (1): 4528) teach determining the kinetic rate and affinity constants between the SARS-CoV-2 spike RBD and purified antibodies by surface plasmon resonance (SPR), see the first full paragraph on the second column on page 2, Figure 1h, and “Affinity measurement and competition-binding study”. There is no discussion or data presented in the instant disclosure regarding kinetic rates or affinity constants or any assay that measures these parameters indicating affinity and increased affinity of neutralizing antibodies to SARS-COV-02 RBD-protein and SARS-COV-02 N-protein in the presence or absence of chitosan, as required and asserted by the instant claims. The skilled artisan would not predict measurements associated with antibody affinity using an ELISA and the prior art is silent with regard to determining antibody affinity using an ELISA. For these reasons, it is determined that an undue quantity of experimentation would be required to make and use the invention claimed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHANON A FOLEY whose telephone number is (571)272-0898. The examiner can normally be reached M-F, generally 5:30 AM-5 PM, flexible. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 571-270-3497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Shanon A. Foley/ Primary Examiner, Art Unit 1671
Read full office action

Prosecution Timeline

Jun 22, 2023
Application Filed
Jan 23, 2026
Non-Final Rejection mailed — §112
May 26, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779026
HIV Immunogens, Vaccines, and Methods Related Thereto
4y 5m to grant Granted Nov 03, 2026
Patent 12779029
RECOMBINANT RSV VACCINE: METHODS OF MAKING AND USING THE SAME
3y 0m to grant Granted Nov 03, 2026
Patent 12773447
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
5y 4m to grant Granted Oct 27, 2026
Patent 12760281
Novel chimpanzee adenovirus vector, construction method therefor, and application thereof
3y 9m to grant Granted Oct 13, 2026
Patent 12741016
C-TERMINUS MODIFIED HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN AND USE THEREOF
3y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.2%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 994 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month